The University of Southampton
University of Southampton Institutional Repository

Potential and novel therapies for asthma

Potential and novel therapies for asthma
Potential and novel therapies for asthma
Asthma is a chronic inflammatory disorder characterised by airflow obstruction. The inflammatory process involves mast cells, antigen presenting cells, eosinophils, neutrophils, airway epithelial cells and TH2 lymphocytes. These cells produce a broad array of pro-inflammatory mediators and cytokines that lead to the pathophysiological changes seen in asthma. The improved understanding of this complex disease, the specific cells and the complex mediators has lead to newer insights into the efficacy of various novel and potential therapies.
In this review, we discuss the pharmacological agents that interrupt the synthesis and action of leukotrienes, cytokine antagonism, monoclonal antibodies against IgEs, selective phosphodiesterase inhibitors, adenosine receptor ligands and immunomodulators to drive the inflammatory response towards a TH1 type and other possible specific targeted therapy for the management of asthma. Although most of these therapies are in the inchoate stages these may hold the future for use in asthma.
0004-5772
1096-1102
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc

Babu, K.S. and Holgate, S.T. (2000) Potential and novel therapies for asthma. The Journal of the Association of Physicians of India, 48 (11), 1096-1102.

Record type: Article

Abstract

Asthma is a chronic inflammatory disorder characterised by airflow obstruction. The inflammatory process involves mast cells, antigen presenting cells, eosinophils, neutrophils, airway epithelial cells and TH2 lymphocytes. These cells produce a broad array of pro-inflammatory mediators and cytokines that lead to the pathophysiological changes seen in asthma. The improved understanding of this complex disease, the specific cells and the complex mediators has lead to newer insights into the efficacy of various novel and potential therapies.
In this review, we discuss the pharmacological agents that interrupt the synthesis and action of leukotrienes, cytokine antagonism, monoclonal antibodies against IgEs, selective phosphodiesterase inhibitors, adenosine receptor ligands and immunomodulators to drive the inflammatory response towards a TH1 type and other possible specific targeted therapy for the management of asthma. Although most of these therapies are in the inchoate stages these may hold the future for use in asthma.

Full text not available from this repository.

More information

Published date: 2000

Identifiers

Local EPrints ID: 26914
URI: http://eprints.soton.ac.uk/id/eprint/26914
ISSN: 0004-5772
PURE UUID: d861cbf1-8907-4e41-b235-a36c673d4a1c

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Jul 2019 19:13

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×